MX379709B - Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. - Google Patents

Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.

Info

Publication number
MX379709B
MX379709B MX2019007327A MX2019007327A MX379709B MX 379709 B MX379709 B MX 379709B MX 2019007327 A MX2019007327 A MX 2019007327A MX 2019007327 A MX2019007327 A MX 2019007327A MX 379709 B MX379709 B MX 379709B
Authority
MX
Mexico
Prior art keywords
salts
thiazolidendione
pyridinyl
ethoxy
hydroxyethyl
Prior art date
Application number
MX2019007327A
Other languages
English (en)
Other versions
MX2019007327A (es
Inventor
Maria Garcia Collazo Ana
Johannes B M Rewinkel
Johannes Nicolaas Koek
Wilde Sander De
Hoeve Wolter Ten
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of MX2019007327A publication Critical patent/MX2019007327A/es
Publication of MX379709B publication Critical patent/MX379709B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona un proceso para preparar el compuesto de la Fórmula I, y sus sales farmacéuticamente aceptables; y el proceso de hacer el intermediario de la Fórmula III: en donde PG es como se define como se establece en la especificación.
MX2019007327A 2016-12-23 2017-12-22 Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. MX379709B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382648 2016-12-23
PCT/IB2017/058374 WO2018116281A1 (en) 2016-12-23 2017-12-22 Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Publications (2)

Publication Number Publication Date
MX2019007327A MX2019007327A (es) 2019-09-02
MX379709B true MX379709B (es) 2025-03-11

Family

ID=57799523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007327A MX379709B (es) 2016-12-23 2017-12-22 Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.

Country Status (18)

Country Link
US (2) US11124505B2 (es)
EP (1) EP3559010B1 (es)
JP (2) JP7294661B2 (es)
KR (1) KR102609373B1 (es)
CN (1) CN110198945B (es)
BR (1) BR112019012972B1 (es)
CA (1) CA3046744A1 (es)
DK (1) DK3559010T3 (es)
ES (1) ES2926580T3 (es)
HR (1) HRP20221067T1 (es)
HU (1) HUE059604T2 (es)
IL (1) IL267557B (es)
LT (1) LT3559010T (es)
MX (1) MX379709B (es)
PL (1) PL3559010T3 (es)
PT (1) PT3559010T (es)
SI (1) SI3559010T1 (es)
WO (1) WO2018116281A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
PL3801515T3 (pl) 2018-06-06 2025-07-14 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych
WO2019234689A1 (en) 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
US20210228558A1 (en) 2018-06-06 2021-07-29 Minoryx Therapeutics S.L. Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
AU2024268104A1 (en) 2023-05-09 2025-11-27 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
HRP20090594T1 (hr) 2005-02-16 2009-12-31 Micromet Ag Upotreba aktiviranih polimera za odvajanje proteina i polipeptidnih multimera
WO2008038692A1 (en) * 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JPWO2008136428A1 (ja) * 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EA201491954A1 (ru) * 2012-04-26 2015-01-30 Бристол-Майерс Сквибб Компани Производные имидазотиадиазола и имидазопиридазина в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
ES2678046T3 (es) * 2014-04-02 2018-08-08 Minoryx Therapeutics S.L. Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Also Published As

Publication number Publication date
US20190389852A1 (en) 2019-12-26
DK3559010T3 (da) 2022-08-15
WO2018116281A1 (en) 2018-06-28
KR102609373B1 (ko) 2023-12-01
EP3559010A1 (en) 2019-10-30
CN110198945B (zh) 2023-06-27
EP3559010B1 (en) 2022-06-08
BR112019012972B1 (pt) 2023-04-18
MX2019007327A (es) 2019-09-02
IL267557B (en) 2021-10-31
IL267557A (en) 2019-08-29
PT3559010T (pt) 2022-09-01
BR112019012972A2 (pt) 2019-12-31
ES2926580T3 (es) 2022-10-27
SI3559010T1 (sl) 2022-10-28
HUE059604T2 (hu) 2022-11-28
US11124505B2 (en) 2021-09-21
JP7294661B2 (ja) 2023-06-20
JP2023052918A (ja) 2023-04-12
HRP20221067T1 (hr) 2022-11-25
PL3559010T3 (pl) 2022-11-21
JP2020502228A (ja) 2020-01-23
CN110198945A (zh) 2019-09-03
CA3046744A1 (en) 2018-06-28
US11731963B2 (en) 2023-08-22
US20220204496A1 (en) 2022-06-30
KR20190100300A (ko) 2019-08-28
LT3559010T (lt) 2022-10-10

Similar Documents

Publication Publication Date Title
MX379709B (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
IL223002A0 (en) Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
PE20160540A1 (es) Inhibidores de bromodominios
IL229395A0 (en) Modified release of4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20160802A1 (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
NZ629636A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
UY34722A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil] etil}amino)-1-hidroxietil]-8- hidroxiquinolin-2(1h)-ona
HUE054346T2 (hu) 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
CO2017002266A2 (es) Derivados de 5-[3-metil-2-[(4-metillsulfonilpiperazin-1-il)metil]-7-morfolinotieno [2,3-c] piridinil como inhibidores de la quinasa pi3
CO6960546A2 (es) Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
DK3298008T3 (da) Krystallinsk form af forbindelsen (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-1,2-diol
PT3801515T (pt) 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona e seus sais para uso no tratamento de doenças mitocondriais
PL2943488T3 (pl) Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
MX375758B (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
MY180730A (en) Azole benzene derivative and crystalline form thereof
HK40025190A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide